Information Services Group, Inc. (III) News
Track canonical SquawkNews coverage tagged to III, Information Services Group, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 16 indexed stories across 15 publication days and is ordered by the same first-publication timeline used by LiveCast.
H
Information Services Gr Reports Q2 2026 Results: Full Earnings Call Transcript
Information Services Gr (NASDAQ: III ) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This content is powered APIs. For comprehensive financial data and tran
LIVE | Sep 17, 2026, 11:39 AM UTC
L
AI Expands Strategic Role of Contact Centers, ISG Says
Contact centers are evolving from reactive, cost-sensitive organizations into customer engagement hubs with growing capabilities enabled by AI and other advances, according to new research from global AI-centered technol
EQUITY | Sep 10, 2026, 02:00 PM UTC
L
3i Group PLC says shares admitted to trading
3i Group plc notified the market that shares have been admitted to trading on a regulated market, citing FCA Prospectus Rules (PRM) sourcebook 1.6.4R. Details are not included in the feed.
EQUITY | Sep 08, 2026, 01:49 PM UTC
L
ISG names 2026 Women in Digital Awards finalists
Information Services Group (Nasdaq: III) announced the finalists for its 2026 ISG Women in Digital Awards, selecting more than 700 finalists for the fifth annual program.
EQUITY | Sep 03, 2026, 02:00 PM UTC
L
France firms prioritize sovereignty in AI and hybrid cloud deployments
A new ISG research report says enterprises in France are moving AI and data-intensive workloads into more controlled private and hybrid cloud environments as sovereignty requirements shape where regulated data can be hos
EQUITY | Sep 03, 2026, 08:00 AM UTC
L
3i Group PLC granted admission to trading
3i Group PLC has been granted admission to trading, according to TradingView News.
EQUITY | Aug 28, 2026, 04:02 PM UTC
L
ISG Announces 2026 ISG Paragon Awards™ Asia Winners
ISG Announces 2026 ISG Paragon Awards™ Asia Winners
EQUITY | Aug 27, 2026, 01:00 AM UTC
L
BAYRY - Bayer to present new phase III data from its cardiovascular, kidney, and stroke clinical trial programs at esc 2026
BAYRY - Bayer to present new phase III data from its cardiovascular, kidney, and stroke clinical trial programs at esc 2026
EQUITY | Aug 20, 2026, 12:02 PM UTC
L
CVX Chevron strengthens north American base oils distribution network Chevron Corp - Hf Sinclair to become exclusive distributor of Chevron
CVX Chevron strengthens north American base oils distribution network Chevron Corp - Hf Sinclair to become exclusive distributor of Chevron group II base oils in Canada and U.S. territories effective may 1, 2027 - Renker
ENERGY | Aug 03, 2026, 11:01 AM UTC
M
III to Study Oracle Cloud
III studies Oracle Cloud technology
EQUITY | Jul 29, 2026, 02:00 PM UTC
L
GSK GSK RESULTS: Q2, Q2 sales GBP 8.409B vs. EST GBP 8.239B, Q2 ADJ operating profit GBP 2.800B vs. EST GBP 2.646B, Q2 ADJ EPS GBP 0.505 vs.
GSK GSK RESULTS: Q2, Q2 sales GBP 8.409B vs. EST GBP 8.239B, Q2 ADJ operating profit GBP 2.800B vs. EST GBP 2.646B, Q2 ADJ EPS GBP 0.505 vs. EST GBP 0.46, Q2 dividend GBP 0.17, GSK Earnings Notes:, Outlook FY core operat
EARNINGS | Jul 28, 2026, 11:00 AM UTC
L
AZN Astrazeneca Plc - update on ultomiris phase III trial in hsct-tma Astrazeneca - ultomiris phase III trial in adults and adolescents with
AZN Astrazeneca Plc - update on ultomiris phase III trial in hsct-tma Astrazeneca - ultomiris phase III trial in adults and adolescents with hsct-tma did not meet primary endpoint - Ultomiris phase III trial in paediatri
EQUITY | Jul 27, 2026, 10:38 AM UTC
L
SMMT +1.85% in pre-mkt trading - earlier PR: Ivonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western a
SMMT +1.85% in pre-mkt trading - earlier PR: Ivonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated Analysis from Global Phase III HARMONi Study Link T
EQUITY | Jul 22, 2026, 12:42 PM UTC
H
SPCX LMT NASA on track for 2027 artemis III mission despite Blue Origin launchpad explosion, administrator notes NASA administrator wants Eu
SPCX LMT NASA on track for 2027 artemis III mission despite Blue Origin launchpad explosion, administrator notes NASA administrator wants European Partners to focus on programs that help US Moon mission
RATES | Jul 20, 2026, 11:38 AM UTC
L
INCPF innocare announces phase III study results of tyk2 inhibitor soficitinib meet primary endpoint in patients with atomic dermatitis Inno
INCPF innocare announces phase III study results of tyk2 inhibitor soficitinib meet primary endpoint in patients with atomic dermatitis Innocare Pharma - soficitinib shows good safety profile with no new safety signals -
EQUITY | Jul 15, 2026, 11:55 AM UTC
L
ISG to Study Power and Utilities Service Providers
Upcoming ISG Provider Lens
EQUITY | Jul 06, 2026, 02:00 PM UTC